Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
2020; Adis, Springer Healthcare; Volume: 5; Issue: 2 Linguagem: Inglês
10.1007/s41669-020-00245-4
ISSN2509-4254
AutoresBen Rothwell, Christopher Kiff, C. Ling, Thor‐Henrik Brodtkorb,
Tópico(s)Economic and Financial Impacts of Cancer
ResumoThe aim of this study was to investigate the cost effectiveness of nivolumab versus docetaxel in previously treated, advanced non-small-cell lung cancer (NSCLC) in England and assess how conditional reimbursement within the Cancer Drugs Fund (CDF) can be used to ensure timely patient access to effective treatments.
Referência(s)